Forte Biosciences, Inc. (FBRX)
NASDAQ
Closed
Aug 28, 2026
Day's Range
76.9952 wk Range
10.11Overview - FBRX - Forte Biosciences, Inc.
Key Statistics
Valuation
Enterprise Value
1.74B
P/E (Trailing)
‪-16.34‬
P/E (Forward)
‪-18.89‬
PEG Ratio
‪-15.69‬
Price / Book
‪10.23‬
EV / EBITDA
‪-18.37‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-37.79%‬
Return on Equity
‪-62.27%‬
Ownership
Shares Outstanding
20.48M
Float
18.66M
Short % of Shares Outstanding
‪7.74%‬
Held by Insiders
‪1.64%‬
Held by Institutions
‪96.65%‬
Price stats
Beta
‪2.64‬
50-Day Avg
‪55.18‬
200-Day Avg
‪33.25‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - FBRX - Forte Biosciences, Inc.
Peers - FBRX - Forte Biosciences, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- FBRXNASDAQForte Biosciences, Inc.1.63BMarket Cap+86.28%52-week change-16.35P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - FBRX - Forte Biosciences, Inc.
About
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. Its primary product candidate is FB102, a proprietary anti-CD122 monoclonal antibody designed to address unmet needs in conditions such as celiac disease, vitiligo,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
